# Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

> **NCT05829317** · PHASE4 · RECRUITING · sponsor: **Dr. Stephanie Sibley** · enrollment: 200 (estimated)

## Conditions studied

- Critical Illness
- New Onset Atrial Fibrillation

## Interventions

- **DRUG:** Magnesium sulfate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05829317
- **Lead sponsor:** Dr. Stephanie Sibley
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-20
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05829317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05829317, "Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05829317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*